Peptide inhibitors of CRISPR-Cas9
| DWPI Title: Agent for use in composition for inhibiting clustered regularly interspaced short palindromic repeats-associated enzyme 9 variants, is selected from amino acid sequences |
| Abstract: Specific and broad-spectrum inhibitory peptides to CRISPR Cas9 variants (SpyCas9, SauCas9, and CjeCas9) are disclosed. A method of making and using these peptides with therapeutic CRISPR Cas9 (to improve desired targeting) or against harmful CRISPR Cas9 components (already active in a patient) is also disclosed. The peptides combined with a delivery system is also disclosed. |
| Use: Agent for use in composition (claimed) for inhibiting Cas9 variants.Test details are described but no results given. |
| Advantage: The agent improves targeting of CRISPR Cas9. |
| Novelty: Agent is selected from an amino acid sequence having at least 90% sequence identity to sequence having 16-22 amino acids of (SEQ ID NOs: 1, 3-10, and 12-28), given in the specification. The sequence identity is calculated over a full length of the amino acid sequence. |
| Filed: 5/6/2020 |
| Application Number: US16867698A |
| Tech ID: SD 15067.0 |
| This invention was made with Government support under Contract No. DE-NA0003525 awarded by the United States Department of Energy/National Nuclear Security Administration. The Government has certain rights in the invention. |
| Data from Derwent World Patents Index, provided by Clarivate All rights reserved. Republication or redistribution of Clarivate content, including by framing or similar means, is prohibited without the prior written consent of Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license. |